PATIENTS WITH TERMINAL CANCER IN COMPLETE REMISSION AFTER ONE GENE THERAPY TREATMENT

A groundbreaking gene therapy treatment which boosts a patient’s own immune cells has been shown to clear disease from one third of terminal patients.

US pharmaceutical company Kite Pharma released results from the first six months of its trial of the new treatment, called CAR-T cell therapy.

Some 36 per cent of the 101 patients on the trial were still in complete remission at six months, and eight in 10 saw their cancer shrink by at least half during the study.

“The numbers are fantastic,” said Dr Fred Locke, a blood cancer expert at Moffitt Cancer Center in Tampa who co-led the study.

“These are heavily treated patients who have no other options.”

The scans show how cancer has disappeared after just three months, and the remission has continued.

The treatment, which has been dubbed ‘a living drug’ by doctors, works by filtering a patient’s blood to remove key immune system cells called T-cells, which are then genetically engineered in the lab to recognise cancer cells.

Cancer cells are very good a evading the immune system, but the new therapy essentially cuts the brakes, allowing immune cells to do their job properly.

Martin Ledwick, Cancer Research UK’s head cancer information nurse, said: “These results are promising and suggest that one day CAR-T cells could become a treatment option for some patients with certain types of lymphoma.

“But, we need to know more about the side effects of the treatment and long term benefits.”

Comments
No. 1-1
atlas
atlas

This is soooo exciting! Amazing how our own body can heal itself with the right information. Can't wait for them to expand the study and start treating other forms of cancer! Wonderful news!